Literature DB >> 26606817

Lung Stereotactic Body Radiation Therapy.

Sana Rehman, Michael C Roach, Jeffrey D Bradley, Cliff G Robinson.   

Abstract

Lung stereotactic body radiation therapy (SBRT) is a novel and effective modality for treatment of early stage non-sail cell lung cancer (NSCLC), with expanding indications in locally advanced and metastatic disease. Herein, we will review current treatment recommendations for early stage NSCLC, detail treatment planning of SBRT, and discuss future directions.

Entities:  

Mesh：

Year:  2015        PMID： 26606817      PMCID： PMC6167240     

Source DB:  PubMed          Journal:  Mo Med        ISSN： 0026-6620


  15 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy.

Authors:  Louis Potters; Brian Kavanagh; James M Galvin; James M Hevezi; Nora A Janjan; David A Larson; Minesh P Mehta; Samuel Ryu; Michael Steinberg; Robert Timmerman; James S Welsh; Seth A Rosenthal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-01       Impact factor: 7.038

3.  Erratum. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927).

Authors:  Gregory M M Videtic; Chen Hu; Anurag K Singh; Joe Y Chang; William Parker; Kenneth R Olivier; Steven E Schild; Ritsuko Komaki; James J Urbanic; Hak Choy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-01       Impact factor: 7.038

4.  Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.

Authors:  Achilles J Fakiris; Ronald C McGarry; Constantin T Yiannoutsos; Lech Papiez; Mark Williams; Mark A Henderson; Robert Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-27       Impact factor: 7.038

5.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

6.  Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy.

Authors:  Kimberly M Creach; Issam El Naqa; Jeffrey D Bradley; Jeffrey R Olsen; Parag J Parikh; Robert E Drzymala; Charles Bloch; Clifford G Robinson
Journal:  Radiother Oncol       Date:  2012-03-03       Impact factor: 6.280

7.  Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy.

Authors:  L Christine Fang; Ritsuko Komaki; Pamela Allen; Thomas Guerrero; Radhe Mohan; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-01       Impact factor: 7.038

8.  Impact of revised stage classification of lung cancer on survival: a military experience.

Authors:  S A Adebonojo; A N Bowser; D M Moritz; P C Corcoran
Journal:  Chest       Date:  1999-06       Impact factor: 9.410

9.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

10.  No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236.

Authors:  Sinisa Stanic; Rebecca Paulus; Robert D Timmerman; Jeff M Michalski; Robert B Barriger; Andrea Bezjak; Gregory M M Videtic; Jeffrey Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.